FDA approves first therapeutic indication for Daxxify for injection for the treatment of cervical dystonia – Revance Therapeutics
Revance Therapeutics, Inc. announced that the FDA has approved the first therapeutic indication for Daxxify (daxibotulinumtoxinA-lanm) for injection for the treatment of cervical dystonia in adults. Daxxify, powered… read more.
